Evotec SE EVO
NASDAQ EVO
$1.93 -0.03 (-1.53%)
At close: Aug 21, 2026 · 4:00 PM EDT

Evotec SE (EVO) Cash from Investing Activities (2009 - 2026)

Evotec SE (EVO) posted Cash from Investing Activities of -$14557.1 for Q1 2026, down 100.01% sequentially from $199.8 million in Q4 2025, and up 35.95% YoY from -$10707.6 in Q1 2025.

Evotec SE (EVO) Cash from Investing Activities (2009 - 2026) Analysis & Trends

Evotec SE has reported Cash from Investing Activities for 9 years, with the latest figure at -$14557.1 in Q1 2026.

  • Quarterly Cash from Investing Activities rose 35.95% year-over-year to -$14557.1 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $199.8 million (up 362.62% YoY) and the FY2025 annual result came in at $199.7 million, up 362.57% from the prior year.
  • Cash from Investing Activities retreated to -$14557.1 in Q1 2026 per EVO's latest filing, from $199.8 million in the prior quarter.
  • Over five years, Cash from Investing Activities peaked at $199.8 million in Q4 2025 and troughed at -$420.7 million in Q4 2022.
  • A 5-year average of -$18.3 million and a median of -$28464.8 in 2024 frame the typical range for Cash from Investing Activities.
  • The sharpest annual moves came in 2022 and 2025: Cash from Investing Activities slumped 191439.37% in 2022, then jumped 362.98% in 2025.
  • Over 5 years, Cash from Investing Activities stood at -$420.7 million in 2022, then jumped by 96.6% to -$14.3 million in 2023, then plunged by 430.62% to -$76.0 million in 2024, then surged by 362.98% to $199.8 million in 2025, then plunged by 100.01% to -$14557.1 in 2026.
  • According to Business Quant data, Cash from Investing Activities over the past three periods registered -$14557.1, $199.8 million, and -$8465.1 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Haleon 44.51 Bn 43.55 Bn - -
2 Teva Pharmaceutical Industries 43.52 Bn 39.86 Bn 2.15 Bn -491.00 Mn
3 Zoetis 32.43 Bn 30.75 Bn 1.05 Bn -300.00 Mn
4 Takeda Pharmaceutical 28.63 Bn 22.83 Bn 5.10 Bn -550.24 Mn
5 United Therapeutics 21.87 Bn 19.21 Bn 683.80 Mn 87.50 Mn
6 Viatris 18.98 Bn 18.09 Bn 1.46 Bn -51.60 Mn
7 Neurocrine Biosciences 15.43 Bn 15.04 Bn 935.80 Mn -135.40 Mn
8 Elanco Animal Health 12.02 Bn 11.49 Bn 798.00 Mn -110.00 Mn
9 Dr Reddys Laboratories 10.14 Bn 9.98 Bn - -
10 Evotec SE 687.23 Mn 686.75 Mn - -14,557.05

Historic Data

Download Data
DateValue
Mar 31, 2026 -14,557.05
Mar 31, 2026 -14,557.05
Dec 31, 2025 199.80 Mn
Dec 31, 2025 199.80 Mn
Sep 30, 2025 -8,465.13
Sep 30, 2025 -8,465.13
Jun 30, 2025 -24,838.59
Jun 30, 2025 -24,838.59
Mar 31, 2025 -22,728.07
Mar 31, 2025 -22,728.07
Dec 31, 2024 -75.98 Mn
Dec 31, 2024 -75.98 Mn
Sep 30, 2024 -28,464.75
Sep 30, 2024 -28,464.75
Jun 30, 2024 -33,687.20
Jun 30, 2024 -33,687.20
Mar 31, 2024 -33,576.18
Mar 31, 2024 -33,576.18
Dec 31, 2023 -14.32 Mn
Dec 31, 2023 -14.32 Mn